Healio: DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19

August 22, 2020

SGLT2 inhibitors could potentially target key mechanisms activated in COVID-19, increasing lipolysis, reducing glycolysis, inflammation and oxidative stress, and improving endothelial function to reduce organ damage, according to a speaker.

“We know that favorable effects on mechanisms such as endothelial function, a key driver of adverse outcomes in COVID-19, can occur very quickly after treatment with SGLT2 inhibitors,” Mikhail Kosiborod, MD, FACC, FAHA, cardiologist at Saint Luke’s Mid America Heart Institute, professor of medicine at the University of Missouri-Kansas City School of Medicine, said during an online presentation during the virtual Heart in Diabetes conference. “If you think through these mechanisms and the fact that SGLT2 inhibitors can have a positive impact on many of them, what becomes clear is that testing SGLT2 inhibitors as potential agents for organ protection in COVID-19 may be one of the key hypotheses.”

Read Healio's full article: DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19

Related Content

COVID-19 testing tube with graph transposed overtop
Saint Luke’s Mid America Heart Institute and AstraZeneca initiate Phase III DARE-19 trial in COVID-19 patients
The trial will assess the potential of dapagliflozin in reducing the risk of serious complications and organ failure.
Blue sphere COVID-19 viruses
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.
KSHB: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment
KSHB: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.